Economic TimesLean R·
US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipeline
ET Intelligence Group: Initial trends in pharma results for the June quarter show pressure on the US business, with a double-digit fall in net profit and contraction in operating profitability. The domestic business continued to be a bright spot for both companies. Obesity therapies, respiratory products, biosimilars and speciality launches are key growth drivers in the coming quarters.Dr Reddy's Labs lost 10% and Cipla 8%, on bourses, underperforming the 10% gain in the BSE Healthcare index ov…
Read at Economic Times →
